1112 On Other Exchanges
Symbol
Exchange
1112 is not on other exchanges.

biostime international holdi (1112) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOSTIME INTERNATIONAL HOLDI (1112)

Related News

No related news articles were found.

biostime international holdi (1112) Related Businessweek News

No Related Businessweek News Found

biostime international holdi (1112) Details

Biostime International Holdings Limited, an investment holding company, provides pediatric nutritional and baby care products to mothers primarily in the People’s Republic of China. The company operates through five segments: Infant Formulas, Adult Nutrition and Care Products, Probiotic Supplements, Dried Baby Food and Nutrition Supplements, and Baby Care Products. The Infant Formulas segment produces infant formulas for children under seven years old and milk formulas for expectant and nursing mothers. The Adult Nutrition and Care Products segment offers vitamins, health supplements, and skin care and sports nutrition products for adults. The Probiotic Supplements segment produces probiotic supplements in the form of sachets, capsules, and tablets for infants, children, and expectant mothers. The Dried Baby Food and Nutrition Supplements segment engages in the production of dried baby food products made from natural foods for infants and young children; and microencapsulated milk calcium chewable tablets for children, and pregnant and lactating mothers. The Baby Care Products segment provides baby care products for infants and children, including baby diapers and toiletry kits, as well as personal care products for nursing mothers, such as nursing pads. The company is also involved in the wholesale, retail, import, and export of personal care products for infants; trading of infant food and nutritional products; early childhood education advisory business; and trading of related baby supplies, as well as offers online software and information technology services. It sells its products and services through distributors under the Biostime, Adimil, BMcare, and Parenting Power brands. The company was founded in 1999 and is headquartered in Guangzhou, China. Biostime International Holdings Limited (China) operates as a subsidiary of Biostime Pharmaceuticals (China) Limited.

2,495 Employees
Last Reported Date: 01/23/17
Founded in 1999

biostime international holdi (1112) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: CNY6.5M
Chief Operating Officer
Total Annual Compensation: CNY3.4M
Compensation as of Fiscal Year 2015.
biostime international holdi
Biostime International Holdings Limited Announces Issuance of $200,000,000 7.25% Senior Notes Due 2021

The Board announced that on 23 January 2017, Biostime International Holdings Limited entered into the purchase agreement with Goldman Sachs in connection with the issue of USD 200,000,000 7.25% Senior Notes due 2021, maturity date is 21 June 2021. The Senior Notes will bear interest from and including 21 December 2016 at a rate of 7.25% per annum, payable semi-annually in arrears. The gross proceeds of the Senior Notes Issue will be USD 209 million. The proceeds of the Senior Notes Issue are expected to be used, together with the Company's cash on hand, to fund the Swisse Minority Acquisition. Initial Subsidiary Guarantors were British Virgin Islands, Cayman Islands, Hong Kong and Australia subsidiaries of the Issuer which are: Biostime International Investment Limited, Biostime Hong Kong Limited, Biostime Healthy (BVI) Limited, Biostime Healthy (Cayman) Limited, Biostime Healthy II (BVI) Limited, Biostime Healthy Hong Kong Limited, Biostime Healthy Australia Investment Pty Ltd, Biostime Healthy Australia Pty Ltd, Biostime Healthy Australia Holdings Pty Ltd, Swisse Wellness Group Pty Ltd, SWG Holdco Pty Ltd. and Swisse Wellness Pty Ltd. The Senior Notes will only be offered and sold in an institutional offering to qualified institutional buyers in the United States in reliance on Rule 144A under the U.S. Securities Act and outside the United States in reliance on Regulation S. Events of default with respect to the Senior Notes include, among others, failure to pay principal, interest or additional amounts. On or after 21 June 2018, the Company may on any one or more occasions redeem all or any part of the Senior Notes, at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest, if any, on the Senior Notes redeemed, to (but not including) the applicable redemption date, if redeemed during the twelve-month period beginning on 21 June of the year.

Biostime International Holdings Limited Proposes to Conduct an International Offering of the Senior Notes

Biostime International Holdings Limited proposed to conduct an international offering of the Senior Notes. The Senior Notes will be issued as additional notes under the Indenture and will form part of the same series as the Original Notes. The Senior Notes will be guaranteed by the Subsidiary Guarantors. The Senior Notes will have the same terms as those of the Original Notes and will be treated as a single class together with the Original Notes and will be fully fungible upon issuance. The Senior Notes will only be offered and sold in an institutional offering to qualified institutional buyers in the United States in reliance on Rule 144A under the U.S. Securities Act and outside the United States in reliance on Regulation S. Goldman Sachs has been appointed as the sole global coordinator, sole lead manager and sole bookrunner in respect of the Proposed Senior Notes Offering. The company, the subsidiary guarantors and Goldman Sachs are expected to enter into the purchase agreement and other ancillary documents in relation to the Senior Notes. The Senior Notes and the Subsidiary Guarantees have not been and will not be registered under the U.S. Securities Act or any state securities laws and are being offered and sold only to (i) ‘qualified institutional buyers’ (as defined in Rule 144A under the U.S. Securities Act) (‘QIBs’) in compliance with Rule 144A and (ii) non-U.S. persons outside the United States in offshore transactions in reliance on Regulation S. None of the Senior Notes or the Subsidiary Guarantees will be offered to the public in Hong Kong and none of the Senior Notes will be placed to any connected persons of the company. In connection with the Proposed Senior Notes Offering, the company will provide certain institutional investors with recent corporate and financial information regarding the group, which may not necessarily have been made public. The company intends to use the net proceeds of the Proposed Senior Notes Offering, together with cash on hand, to fund the Swisse Minority Acquisition. Approval in-principle has been received for the listing and quotation of the Senior Notes on the Official List of the SGX-ST. Such approval in-principle is not to be taken as an indication of the merits of the company, its subsidiaries, or the Senior Notes. The SGX-ST assumes no responsibility for the correctness of any of the statements made, opinions expressed or reports contained herein. No listing of the Senior Notes has been, or will be, sought in Hong Kong.

Biostime International Holdings Limited Presents at Citi Hong Kong and China Corporate Day 2017 (Theme: Consumer), Jan-20-2017

Biostime International Holdings Limited Presents at Citi Hong Kong and China Corporate Day 2017 (Theme: Consumer), Jan-20-2017 . Venue: Four Seasons Hotel, Hong Kong.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1112 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1112.
View Industry Companies
 

Industry Analysis

1112

Industry Average

Valuation 1112 Industry Range
Price/Earnings 14.0x
Price/Sales 2.1x
Price/Book 4.7x
Price/Cash Flow 13.7x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BIOSTIME INTERNATIONAL HOLDI, please visit www.biostime.com.cn. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.